PURPOSE: Oral mucositis (OM) is a common, painful side effect of radiation therapy used for the treatment of head and neck cancer (HNC). Activation of the innate immune system upon irradiation has been identified as a key precipitating event of OM. To better understand OM's pathogenesis, we studied pattern recognition receptors (PRRs) and their downstream pro-inflammatory cytokines in a mouse model of radiation-induced OM. We also tested therapeutic efficacy of GM-1111 that targets innate immune system to reduce radiation-induced OM. METHODS AND MATERIALS: The pathogenesis of OM was studied in a single X-ray induced mouse model. The severity of OM was measured by visual and microscopical examinations. The irradiation-induced changes of PRRs and their downstream effector cytokine gene expression levels were determined. The efficacy of GM-1111 to reduce OM was tested in single and fractionated irradiation mouse models. The impact of the drug on tumor response to radiation therapy was also tested in a mouse model of human HNC. RESULTS: Radiation-induced tissue ulcerations were radiation-dosage and -time dependent. The lesions showed selective increases in PRR and pro-inflammatory cytokine gene expression levels. Once daily administration of GM-1111 (≥30 mg/kg, s.c.) significantly reduced the severity and the incidence of OM. The drug had little effect on PRRs but significantly inhibited downstream pro-inflammatory cytokine genes. GM-1111 did not interfere radiation therapy to induce HNC SCC-25 tumor regression. Instead, we observed significant drug-induced tumor regression. CONCLUSIONS: Radiation induces tissue damages. The increased expression levels of PRRs and their downstream pro-inflammatory cytokine genes in the damaged tissues suggest their important contribution to the pathogenesis of OM. Drug GM-1111 that targets these innate immune molecules may be a potential drug candidate as an intervention for OM.
PURPOSE:Oral mucositis (OM) is a common, painful side effect of radiation therapy used for the treatment of head and neck cancer (HNC). Activation of the innate immune system upon irradiation has been identified as a key precipitating event of OM. To better understand OM's pathogenesis, we studied pattern recognition receptors (PRRs) and their downstream pro-inflammatory cytokines in a mouse model of radiation-induced OM. We also tested therapeutic efficacy of GM-1111 that targets innate immune system to reduce radiation-induced OM. METHODS AND MATERIALS: The pathogenesis of OM was studied in a single X-ray induced mouse model. The severity of OM was measured by visual and microscopical examinations. The irradiation-induced changes of PRRs and their downstream effector cytokine gene expression levels were determined. The efficacy of GM-1111 to reduce OM was tested in single and fractionated irradiation mouse models. The impact of the drug on tumor response to radiation therapy was also tested in a mouse model of human HNC. RESULTS: Radiation-induced tissue ulcerations were radiation-dosage and -time dependent. The lesions showed selective increases in PRR and pro-inflammatory cytokine gene expression levels. Once daily administration of GM-1111 (≥30 mg/kg, s.c.) significantly reduced the severity and the incidence of OM. The drug had little effect on PRRs but significantly inhibited downstream pro-inflammatory cytokine genes. GM-1111 did not interfere radiation therapy to induce HNC SCC-25tumor regression. Instead, we observed significant drug-induced tumor regression. CONCLUSIONS: Radiation induces tissue damages. The increased expression levels of PRRs and their downstream pro-inflammatory cytokine genes in the damaged tissues suggest their important contribution to the pathogenesis of OM. Drug GM-1111 that targets these innate immune molecules may be a potential drug candidate as an intervention for OM.
Authors: Seung-Hee Ryu; Ki Mun Kang; Soo Young Moon; Gyu Young Chai; Joon Pio Hong; Kyoung-Oh Cho; Mun-Il Kang; Eun Kyung Choi; Sang-wook Lee Journal: J Radiat Res Date: 2010 Impact factor: 2.724
Authors: Thierry M Muanza; Ana P Cotrim; Mathew McAuliffe; Anastasia L Sowers; Bruce J Baum; John A Cook; Felix Feldchtein; Paul Amazeen; C Norman Coleman; James B Mitchell Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: Ourania Nicolatou-Galitis; Triantafyllia Sarri; Joanne Bowen; Mario Di Palma; Vassilios E Kouloulias; Pasquale Niscola; Dorothea Riesenbeck; Monique Stokman; Wim Tissing; Eric Yeoh; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-10-03 Impact factor: 3.603
Authors: Nathan A Bracey; Paul L Beck; Daniel A Muruve; Simon A Hirota; Jiqing Guo; Habib Jabagi; James R Wright; Justin A Macdonald; James P Lees-Miller; Daniel Roach; Lisa M Semeniuk; Henry J Duff Journal: Exp Physiol Date: 2012-07-30 Impact factor: 2.969
Authors: Rachael Brake; Charlie Starnes; John Lu; Danlin Chen; Suijin Yang; Robert Radinsky; Luis Borges Journal: Mol Cancer Res Date: 2008-08 Impact factor: 5.852
Authors: Ritesh K Srivastava; Yong Wang; Jasim Khan; Suhail Muzaffar; Madison B Lee; Zhiping Weng; Claire Croutch; Anupam Agarwal; Jessy Deshane; Mohammad Athar Journal: Ann N Y Acad Sci Date: 2022-06-09 Impact factor: 6.499